Bilder G E, Sweet C S, Emmert S E, Schofield T L, Medina R, Stabilito I I, Friedman P A
Merck, Sharp, and Dohme Research Laboratories, West Point, Pennsylvania 19486.
Endocrinology. 1989 Mar;124(3):1515-21. doi: 10.1210/endo-124-3-1515.
To evaluate the role of atrial natriuretic factor (ANF) in chronic heart failure (HF), the biosynthesis and storage of ANF in cardiac and noncardiac tissues and the level of plasma ANF were measured in rats exhibiting minimal [2-fold rise in left ventricular end diastolic pressure; myocardial infarct (MI) scar length, 25% left ventricle (LV)] and moderate-severe (3-fold rise in left ventricular end diastolic pressure; decreased contractility (dp/dtmax); MI scar length, 47% LV) chronic HF 30 and 60 days after coronary arterial ligation. In rats with moderate-severe HF (30 days post-MI), the cardiac ANF mRNA concentration (determined by dot blot analysis) increased in three heart chambers [LV, 6-fold; left atria (LA), 3-fold; right ventricle (RV), 2-fold], cardiac immunoreactive ANF (IRANF; determined by RIA) concentration increased on the left side (LV, 7-fold; LA, 33%), but was unchanged (RV) or reduced on the right side (right atria, 33%), and plasma IRANF increased 3-fold above sham control values. Excluding the LV (used for MI scar length), the pattern and magnitude of change in ANF mRNA concentration in moderate-severe HF at 60 days were similar to those at 30 days; the cardiac IRANF concentration at this time was the same (LA) or less than (RV, 66%) sham values, and plasma IRANF increased 6-fold above respective sham values. Generally, the changes in the concentrations of cardiac ANF message and peptide and levels of circulating ANF peptide were smaller in rats with minimal HF. The minute quantities of ANF mRNA and IRANF detected in noncardiac tissues (lung, liver, pituitary, aortic arch, brain, kidney, and salivary gland) were unaltered by HF. These findings show that chronic HF, as defined by hemodynamic and histological measurements, specifically and continuously stimulates atrial as well as ventricular ANF biosynthesis; levels of plasma and cardiac ANF are increased early in HF, but with time are subject to modulation. The cardiac ANF system is the prime locus for the effects of HF, as noncardiac ANF biosynthesis and storage are undisturbed by chronic HF.
为评估心房利钠因子(ANF)在慢性心力衰竭(HF)中的作用,在冠状动脉结扎后30天和60天,对表现为轻度[左心室舒张末期压力升高2倍;心肌梗死(MI)瘢痕长度,占左心室(LV)的25%]和中重度(左心室舒张末期压力升高3倍;收缩性降低(dp/dtmax);MI瘢痕长度,占LV的47%)慢性HF的大鼠,测量了心脏和非心脏组织中ANF的生物合成和储存以及血浆ANF水平。在中重度HF大鼠(MI后30天)中,三个心腔的心脏ANF mRNA浓度(通过斑点印迹分析测定)均升高[LV,升高6倍;左心房(LA),升高3倍;右心室(RV),升高2倍],心脏免疫反应性ANF(IRANF;通过放射免疫分析测定)浓度在左侧升高(LV,升高7倍;LA,升高33%),但右侧未改变(RV)或降低(右心房,降低33%),血浆IRANF比假手术对照组值升高3倍。除LV(用于测量MI瘢痕长度)外,60天时中重度HF中ANF mRNA浓度的变化模式和幅度与30天时相似;此时心脏IRANF浓度与假手术组相同(LA)或低于假手术组(RV,降低66%),血浆IRANF比各自假手术组值升高6倍。一般来说,轻度HF大鼠心脏ANF信息和肽的浓度以及循环ANF肽水平的变化较小。在非心脏组织(肺、肝、垂体、主动脉弓、脑、肾和唾液腺)中检测到的微量ANF mRNA和IRANF不受HF影响。这些发现表明,根据血流动力学和组织学测量定义的慢性HF特异性且持续地刺激心房以及心室ANF的生物合成;HF早期血浆和心脏ANF水平升高,但随时间会受到调节。心脏ANF系统是HF作用的主要部位,因为慢性HF不会干扰非心脏ANF的生物合成和储存。